Yutaka Fujiwara1, Yasuo Takahashi2, Morihito Okada3, Takumi Kishimoto4, Shunsuke Kondo5, Koshi Fujikawa2, Manabu Hayama6, Masatoshi Sugeno6, Shinya Ueda6, Keiko Komuro6, Mark Lanasa7, Takashi Nakano8. 1. National Cancer Center Hospital, Tokyo, Japan and Aichi Cancer Center, Nagoya, Japan. 2. National Hospital Organization Hokkaido Cancer Centre, Sapporo, Japan. 3. Hiroshima University Hospital, Hiroshima, Japan. 4. Okayama Rosai Hospital, Okayama, Japan. 5. National Cancer Center Hospital, Tokyo, Japan. 6. AstraZeneca, Osaka, Japan. 7. AstraZeneca, Gaithersburg, MD, USA. 8. Hyogo College of Medicine Hospital, Hyogo, Japan and Otemae Hospital, Osaka, Japan.
Abstract
BACKGROUND: The primary objective of this phase I, open-label trial was to assess safety and tolerability of tremelimumab monotherapy and combination therapy with durvalumab in Japanese patients with advanced cancer. Tremelimumab is a fully human monoclonal antibody against CTLA-4 in clinical trials; durvalumab is a monoclonal antibody against PD-L1 for the treatment of bladder and lung cancer. METHODS: In part 1, tremelimumab 3 or 10 mg/kg was given every 4 weeks (Q4W) for 6 doses, and thereafter every 12 weeks until discontinuation (n = 8); subsequently tremelimumab 10 mg/kg Q4W for 6 doses/Q12W and thereafter until discontinuation was administered in 41 patients with malignant pleural or peritoneal mesothelioma (MPM). In part 2, tremelimumab 10 mg/kg (Q4W for 6 doses followed by Q12W for 3 doses) was given in combination with durvalumab 15 mg/kg (Q4W for 13 doses) in cohort 1 (n = 4). In cohort 2 (n = 6), tremelimumab 1 mg/kg (Q4W for 4 doses) was given in combination with durvalumab 20 mg/kg (Q4W for 4 doses followed by 10 mg/kg Q2W for 22 doses), while in cohort 3 (n = 6), fixed-dose tremelimumab 75 mg Q4W for 4 doses plus durvalumab 1500 mg Q4W for 13 doses was given. RESULTS: In part 1, no dose-limiting toxicities (DLTs) for tremelimumab 3 or 10 mg/kg (Q4W for 6 doses/Q12W thereafter until discontinuation) were observed. Six (75%) patients reported treatment-related adverse events (trAEs). In the MPM dose-expansion cohort, 38 (92.7%) patients reported trAEs. In part 2, one DLT (Grade 4 myasthenia gravis) was reported for tremelimumab 10 mg/kg (Q4W for 6 doses/Q12W for 3 doses) plus durvalumab 15 mg/kg (Q4W for 13 doses). One DLT (Grade 4 hyperglycemia) was reported for tremelimumab 75 mg (Q4W for 4 doses) plus durvalumab 1500 mg (Q4W for 13 doses). Fourteen (87.5%) patients reported trAEs. Tremelimumab demonstrated low immunogenicity; 1 (16.7%) patient developed antidrug antibodies. CONCLUSION: Tremelimumab 10 mg/kg (Q4W/Q12W), tremelimumab 1 mg/kg (Q4W) plus durvalumab 20 mg/kg (Q4W/10 mg/kg Q2W), and fixed-dose tremelimumab 75 mg (Q4W) plus durvalumab 1500 mg (Q4W) were safe and tolerable.ClinicalTrials.gov Identifier: NCT02141347 (https://clinicaltrials.gov/ct2/show/NCT02141347). Published by Oxford University Press 2022.
BACKGROUND: The primary objective of this phase I, open-label trial was to assess safety and tolerability of tremelimumab monotherapy and combination therapy with durvalumab in Japanese patients with advanced cancer. Tremelimumab is a fully human monoclonal antibody against CTLA-4 in clinical trials; durvalumab is a monoclonal antibody against PD-L1 for the treatment of bladder and lung cancer. METHODS: In part 1, tremelimumab 3 or 10 mg/kg was given every 4 weeks (Q4W) for 6 doses, and thereafter every 12 weeks until discontinuation (n = 8); subsequently tremelimumab 10 mg/kg Q4W for 6 doses/Q12W and thereafter until discontinuation was administered in 41 patients with malignant pleural or peritoneal mesothelioma (MPM). In part 2, tremelimumab 10 mg/kg (Q4W for 6 doses followed by Q12W for 3 doses) was given in combination with durvalumab 15 mg/kg (Q4W for 13 doses) in cohort 1 (n = 4). In cohort 2 (n = 6), tremelimumab 1 mg/kg (Q4W for 4 doses) was given in combination with durvalumab 20 mg/kg (Q4W for 4 doses followed by 10 mg/kg Q2W for 22 doses), while in cohort 3 (n = 6), fixed-dose tremelimumab 75 mg Q4W for 4 doses plus durvalumab 1500 mg Q4W for 13 doses was given. RESULTS: In part 1, no dose-limiting toxicities (DLTs) for tremelimumab 3 or 10 mg/kg (Q4W for 6 doses/Q12W thereafter until discontinuation) were observed. Six (75%) patients reported treatment-related adverse events (trAEs). In the MPM dose-expansion cohort, 38 (92.7%) patients reported trAEs. In part 2, one DLT (Grade 4 myasthenia gravis) was reported for tremelimumab 10 mg/kg (Q4W for 6 doses/Q12W for 3 doses) plus durvalumab 15 mg/kg (Q4W for 13 doses). One DLT (Grade 4 hyperglycemia) was reported for tremelimumab 75 mg (Q4W for 4 doses) plus durvalumab 1500 mg (Q4W for 13 doses). Fourteen (87.5%) patients reported trAEs. Tremelimumab demonstrated low immunogenicity; 1 (16.7%) patient developed antidrug antibodies. CONCLUSION: Tremelimumab 10 mg/kg (Q4W/Q12W), tremelimumab 1 mg/kg (Q4W) plus durvalumab 20 mg/kg (Q4W/10 mg/kg Q2W), and fixed-dose tremelimumab 75 mg (Q4W) plus durvalumab 1500 mg (Q4W) were safe and tolerable.ClinicalTrials.gov Identifier: NCT02141347 (https://clinicaltrials.gov/ct2/show/NCT02141347). Published by Oxford University Press 2022.
Authors: Antoni Ribas; Luis H Camacho; Gabriel Lopez-Berestein; Dmitri Pavlov; Cecile A Bulanhagui; Robert Millham; Begoña Comin-Anduix; James M Reuben; Elisabeth Seja; Charla A Parker; Amarnath Sharma; John A Glaspy; Jesus Gomez-Navarro Journal: J Clin Oncol Date: 2005-10-03 Impact factor: 44.544
Authors: Pia Kvistborg; Daisy Philips; Sander Kelderman; Lois Hageman; Christian Ottensmeier; Deborah Joseph-Pietras; Marij J P Welters; Sjoerd van der Burg; Ellen Kapiteijn; Olivier Michielin; Emanuela Romano; Carsten Linnemann; Daniel Speiser; Christian Blank; John B Haanen; Ton N Schumacher Journal: Sci Transl Med Date: 2014-09-17 Impact factor: 17.956
Authors: Scott Antonia; Sarah B Goldberg; Ani Balmanoukian; Jamie E Chaft; Rachel E Sanborn; Ashok Gupta; Rajesh Narwal; Keith Steele; Yu Gu; Joyson J Karakunnel; Naiyer A Rizvi Journal: Lancet Oncol Date: 2016-02-06 Impact factor: 41.316
Authors: Luana Calabrò; Aldo Morra; Diana Giannarelli; Giovanni Amato; Armida D'Incecco; Alessia Covre; Arthur Lewis; Marlon C Rebelatto; Riccardo Danielli; Maresa Altomonte; Anna Maria Di Giacomo; Michele Maio Journal: Lancet Respir Med Date: 2018-05-15 Impact factor: 30.700
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2017-09-08 Impact factor: 91.245
Authors: Patrick M Forde; Valsamo Anagnostou; Zhuoxin Sun; Suzanne E Dahlberg; Hedy L Kindler; Noushin Niknafs; Thomas Purcell; Rafael Santana-Davila; Arkadiusz Z Dudek; Hossein Borghaei; Mara Lanis; Zineb Belcaid; Kellie N Smith; Archana Balan; James R White; Christopher Cherry; I K Ashok Sivakumar; Xiaoshan M Shao; Hok Yee Chan; Dipika Singh; Sampriti Thapa; Peter B Illei; Drew M Pardoll; Rachel Karchin; Victor E Velculescu; Julie R Brahmer; Suresh S Ramalingam Journal: Nat Med Date: 2021-11-08 Impact factor: 53.440